The July edition of the Journal Club has us taking a look at a recent paper that casts doubt and concern over the use of CRISPR Cas9 for gene editing.
If you like watching these streams and/or would like to participate in future streams, please consider supporting us by becoming a Lifespan Hero: https://www.lifespan.io/hero
The paper we are discussing can be found here: https://www.nature.com/articles/nbt.
A research team at the University of Texas Medical Branch have bioengineered lungs and transplanted them into adult pigs with no medical complication.
In 2014, Joan Nichols and Joaquin Cortiella from The University of Texas Medical Branch at Galveston were the first research team to successfully bioengineer human lungs in a lab. In a paper now available in Science Translational Medicine, they provide details of how their work has progressed from 2014 to the point no complications have occurred in the pigs as part of standard preclinical testing.
“The number of people who have developed severe lung injuries has increased worldwide, while the number of available transplantable organs have decreased,” said Cortiella, professor of pediatric anesthesia. “Our ultimate goal is to eventually provide new options for the many people awaiting a transplant,” said Nichols, professor of internal medicine and associate director of the Galveston National Laboratory at UTMB.
Grow-your-own organs could be available for desperately ill patients within five years, after scientists successfully transplanted bioengineered lungs into pigs for the first time.
The team at the University of Texas Medical Branch (UTMB) showed that lab-grown organs were quickly accepted by the animals, and within just two weeks had developed a network of blood vessels.
Previous attempts have failed with several hours of transplantation because the organs did not establish the complicated web of vessels needed for proper oxygen and blood flow.
Few in life get to walk on the Moon. Samsung says, do what you can’t. Working with creative agency Iris and engineering experts Mannetron, Framestore proudly joined Samsung’s mission to bring space travel to all, in the approach to the 50th anniversary of the first lunar landing. ‘A Moon For All Mankind’ is the world’s first lunar gravity simulation VR experience, created in collaboration with NASA Johnson Space Center (JSC), using the Samsung Gear VR and a custom-built rig. Having launched under embargo at the 2018 Winter Olympics and at Mobile World Congress, July sees the experience land publicly at Samsung 837, in New York City.
Posted in bioengineering, biotech/medical, food, genetics, robotics/AI, transhumanism
I’m excited to share I’ll be speaking/debating at the upcoming #Biohack the Planet 2018 conference in Oakland on Aug 31 & Sept 1. Many interesting biohackers will be there. Tickets are still available and very reasonably priced right now, but they will likely sell out. Hope to see you there! Here’s the speaker list: http://biohacktheplanet.com/2018-speakers/ #transhumanism #biohacker & ticket page: https://www.eventbrite.com/e/biohack-the-planet-2018-ticket…
Bryan Johnson is the founder and CEO of Kernel, OS Fund and Braintree.
In 2016, Bryan invested $100M in Kernel to build advanced neural interfaces to treat disease and dysfunction, illuminate the mechanisms of intelligence, and extend cognition. Kernel is on a mission to dramatically increase our quality of life as healthy lifespans extend. He believes that the future of humanity will be defined by the combination of human and artificial intelligence (HI +AI). In 2014, Bryan invested $100M to start OS Fund which invests in entrepreneurs commercializing breakthrough discoveries in genomics, synthetic biology, artificial intelligence, precision automation, and new materials development. Bryan founded Braintree in 2007, later acquiring Venmo, which he sold to Ebay in 2013 for $800M. He is an outdoor-adventure enthusiast, pilot, and author of a children’s book, Code 7.
When CRISPR-Cas9 is used to edit genomes, off-target DNA damage is more common than previously thought.
A GREAT deal rides on the accuracy of the gene-editing tool known as CRISPR-Cas9. Since its discovery in 2012 it has become popular for tinkering with genomes of all kinds, thanks to its ability to make editing cheap and easy. Firms such as CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine have been built on the idea that it could be used to develop treatments for human diseases. Editas, based in Cambridge, Massachusetts, announced this year that it would work on five new human medicines over the next five years.
In China the technology is already in clinical use. In Hangzhou Cancer Hospital, for example, CRISPR-Cas9 is being employed to engineer immune-system cells removed from patients with cancer of the oesophagus. The hope is that when the engineered cells are returned to a patient’s body, the editing will have improved their ability to attack tumours. More studies involving human beings are expected in other countries for the treatment of beta-thalassaemia, a blood disorder, and Leber’s congenital amaurosis, a form of blindness. Further ahead, there is hope that CRISPR-Cas9 will help treat diseases such as AIDS, cystic fibrosis, Huntington’s chorea and Duchenne muscular dystrophy.
Get our daily newsletter
The race to produce safe, powerful and affordable solid-state lithium batteries is accelerating and recent announcements about game-changing research using a solid non-flammable ceramic electrolyte known as garnet has some in the race calling it revolutionary.
“This is a paradigm shift in energy storage,” said Kelsey Hatzell, assistant professor of mechanical engineering. A paper – “The Effect of Pore Connectivity on Li Dendrite Propagation Within LLZO Electrolytes Observed with Synchrotron X-ray Tomography” – describing her novel research on the failure points of a garnet electrolyte was published online in March in the American Chemical Society’s Energy Letters, which was among the most read ACS Letters articles that month.
Lithium-ion batteries typically contain a liquid organic electrolyte that can catch fire. The fire risk is eliminated by the use of a non-flammable garnet-based electrolyte. Replacing liquid electrolytes with a solid organic like garnet also potentially lowers the cost by increasing battery life.
